Acute Graft-versus-Host Disease: An Update on New Treatment Options

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Acute graft-versus-host disease (GVHD) affects approximately 50% of patients post-transplant.
• GVHD is a major cause of transplant-related mortality and non-relapse mortality.
• Effective prevention and treatment are crucial for improving patient outcomes.

Purpose of the Study:

• To review current and emerging strategies for preventing acute GVHD.
• To discuss established and novel therapeutic approaches for treating acute GVHD.
• To highlight the role of JAK inhibitors in GVHD management.

Main Methods:

• Review of clinical data on GVHD prevention strategies (T-cell depletion).
• Analysis of treatment modalities for acute GVHD.
• Evaluation of JAK/STAT pathway inhibitors in GVHD treatment and prevention.

Main Results:

• Prevention via T-cell depletion is a primary strategy.
• JAK inhibitors are standard in second-line treatment and explored for upfront use.
• Salvage therapies beyond second-line remain suboptimal.

Conclusions:

• Optimizing GVHD prevention is key to reducing mortality.
• JAK inhibitors show promise in both prevention and treatment settings.
• Further research is needed for improved salvage therapies.